Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.

ABSTRACT: Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to degrade target proteins by hijacking the ubiquitin-proteasome system, have the potential to revolutionize the healthcare industry. The broad applicability of this protein degradation strategy has been verified with a few E3 ligases and a variety of distinct targets through the construction of modular chimeric structures. Despite recent efforts to promote the use of PROTACs for clinical applications, most PROTACs do not make it beyond the preclinical stage of drug development. There are several reasons that prevent PROTACs from reaching the market, and the inadequate delivery to the target site is one of the most challenging hurdles. With the increasing need for accelerating the translational process, combi

SUBMITTER: Chen Y 

PROVIDER: S-EPMC9382890 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature